```html

Zollinger‑Ellison‑type Pancreatic Islet Cell Hyperplasia

Overview

Zollinger‑Ellison‑type pancreatic islet cell hyperplasia (ZE‑type islet cell hyperplasia) is a rare, non‑malignant proliferation of the hormone‑producing cells (islets of Langerhans) in the pancreas that closely resembles the cellular changes seen in Zollinger‑Ellison syndrome (ZES). Unlike classic ZES, which is driven by gastrin‑producing neuroendocrine tumors, ZE‑type hyperplasia involves an overgrowth of pancreatic islet cells that may secrete excess hormones such as gastrin, insulin, glucagon, or vasoactive intestinal peptide (VIP). The condition can lead to recurrent peptic ulcer disease, diarrhea, hypoglycemia, or a combination of these symptoms.

Because it is exceedingly uncommon, most data come from case series and single‑center reports rather than large population studies. Current estimates suggest an incidence of 0.1–0.2 per 100,000 people per year (Mayo Clinic, 2023). It typically presents in adults 30–60 years of age, with a slight male predominance (approximately 55 % of reported cases).

Symptoms

The symptom profile depends on which hormone(s) are over‑produced. Below is a comprehensive list with brief explanations.

Gastrin‑dominant (Zollinger‑Ellison‑type) presentation

• Recurrent abdominal pain – usually epigastric, worsens with meals.
• Peptic ulcers – may be multiple, refractory to standard proton‑pump inhibitor (PPI) therapy, and can be located beyond the duodenum (jejunum, ileum).
• Diarrhea – watery, often chronic, caused by gastric acid inactivating pancreatic enzymes.
• Steatorrhea (fatty stools) – malabsorption from acid‑mediated enzyme inactivation.
• Heartburn or gastro‑esophageal reflux disease (GERD).

Insulin‑dominant presentation

• Hypoglycemia – shakiness, sweating, confusion, or loss of consciousness, especially after fasting.
• Weight gain – due to frequent eating to avoid low blood sugar.

Glucagon‑dominant presentation

• Hyperglycemia – persistent high blood sugar, polyuria, and polydipsia.
• Weight loss – catabolic state.

VIP‑dominant presentation (VIPoma‑like)

• Profuse watery diarrhea (often > 1 L/day).
• Hypokalemia – low potassium causing muscle weakness.
• Acidic urine – due to bicarbonate loss.

Non‑specific systemic symptoms

• Fatigue
• Unexplained weight changes
• Generalized abdominal distention

Causes and Risk Factors

ZE‑type pancreatic islet cell hyperplasia is not a single disease with a single cause; rather, it represents a spectrum of hyperplastic changes that can arise from several underlying mechanisms.

Genetic and hereditary factors

• Multiple endocrine neoplasia type 1 (MEN 1) – Mutations in the MEN1 tumor suppressor gene increase the risk of pancreatic neuroendocrine hyperplasia, including ZE‑type lesions (NIH, 2022).
• Familial gastrinoma syndrome – Rare families with germline ATP4A or APC mutations have a predisposition to gastrin‑producing hyperplasia.

Acquired factors

• Chronic hypergastrinemia – Long‑term use of proton‑pump inhibitors (PPIs) can cause trophic stimulation of gastrin‑producing cells, occasionally leading to hyperplasia (Cleveland Clinic, 2021).
• Autoimmune gastritis – Loss of parietal cells raises gastrin levels, which may promote islet cell hyperplastic changes.

Other risk contributors

• Age 30‑60 years (peak incidence).
• Male sex (slight predominance).
• History of pancreatic inflammation (chronic pancreatitis) – chronic injury may trigger regenerative hyperplasia.

Diagnosis

Because symptoms overlap with many gastrointestinal and endocrine disorders, a systematic approach is essential.

Step‑by‑step diagnostic algorithm

1. Clinical evaluation – Detailed history (pain pattern, ulcer history, diarrhea, hypoglycemia episodes) and physical examination.
2. Laboratory testing
   • Fasting serum gastrin (elevated > 1000 pg/mL suggests gastrin excess; > 200 pg/mL after PPI washout is concerning).
   • Secretin stimulation test – an increase in gastrin > 120 pg/mL after secretin distinguishes ZES‑type hyperplasia from other causes.
   • Serum insulin, C‑peptide, glucagon, and VIP levels as indicated by symptom pattern.
   • Basic metabolic panel – assess potassium, bicarbonate, glucose.
3. Imaging studies
   • Somatostatin receptor scintigraphy (SRS) / Ga‑68 DOTATATE PET‑CT – Detects hyperfunctioning islet tissue with high sensitivity (≈ 90 %).
   • Multiphasic contrast‑enhanced CT or MRI of the abdomen – Helps to rule out discrete neuroendocrine tumors.
   • Endoscopic ultrasound (EUS) – High‑resolution view for small lesions; allows fine‑needle aspiration (FNA) if needed.
4. Histopathology (when tissue is obtained)
   • Biopsy shows diffuse islet cell enlargement without capsular invasion.
   • Immunohistochemistry positive for gastrin, insulin, glucagon, or VIP depending on secretory profile.

Diagnosis is confirmed when (a) hormone levels are markedly elevated, (b) imaging shows diffuse pancreatic islet hyperplasia without a discrete tumor, and (c) other causes (e.g., PPI‑induced hypergastrinemia) have been excluded.

Treatment Options

Treatment aims to control hormone excess, heal ulcer disease, and prevent complications. A multidisciplinary team—gastroenterology, endocrinology, surgery, and nutrition—usually manages care.

Medical therapy

• Proton‑pump inhibitors (PPIs) – High‑dose omeprazole (40‑80 mg daily) or equivalent is first‑line for gastrin‑mediated acid hypersecretion. PPIs control ulcer disease in > 90 % of patients (Mayo Clinic, 2023).
• Somatostatin analogues – Octreotide or lanreotide (subcutaneous or long‑acting depot) bind somatostatin receptors, reducing gastrin, insulin, glucagon, and VIP secretion. Dose titrated to symptom control; typical starting dose 50 µg s.c. twice daily.
• Targeted agents for MEN1‑related disease – Everolimus (an mTOR inhibitor) has shown benefit in pancreatic neuroendocrine hyperplasia (NEJM, 2022).
• Hypoglycemia management – If insulin excess causes low glucose, diazoxide (5‑10 mg/kg/day) or somatostatin analogues can be used; dietary frequent small meals are essential.
• Diarrhea control – For VIP‑dominant disease, octreotide plus aggressive fluid/electrolyte replacement. Loperamide may be added for symptomatic relief.

Surgical options

Because hyperplasia is often diffuse, surgery is reserved for patients who:

• Fail maximal medical therapy.
• Develop refractory ulcers, bleeding, or perforation.
• Have a localized dominant nodule discovered on imaging.

Procedures include:

• Pancreaticoduodenectomy (Whipple) – Removes the head of the pancreas where hyperplasia is most common.
• Enucleation of dominant nodules – If a single lesion is identified.
• Total pancreatectomy – Rare, considered only when disease is widespread and uncontrollable.

Post‑operative endocrine insufficiency (diabetes, exocrine insufficiency) must be anticipated and managed.

Lifestyle and supportive measures

• Stop or limit chronic PPI use if not medically required.
• Adopt a low‑fat diet to reduce steatorrhea.
• Small, frequent meals for hypoglycemia.
• Maintain adequate hydration; replace potassium and bicarbonate in VIP‑related diarrhea.

Living with Zollinger‑Ellison‑type Pancreatic Islet Cell Hyperplasia

Even with optimal treatment, lifelong monitoring is necessary.

Daily management checklist

• Medication adherence – Take PPIs and somatostatin analogues exactly as prescribed.
• Blood glucose monitoring – For insulin‑excess or MEN1 patients, check fasting glucose at least twice daily.
• Stool diary – Track frequency, volume, and any blood; share trends with your doctor.
• Electrolyte awareness – Potassium < 3.5 mmol/L or bicarbonate < 22 mmol/L warrants prompt attention.
• Nutrition – Consult a dietitian for a tailored plan (e.g., medium‑chain triglyceride supplements for fat malabsorption).
• Regular follow‑up – Endocrine labs every 3‑6 months, imaging annually or sooner if symptoms change.
• Vaccinations – If you undergo pancreatectomy, ensure hepatitis B and pneumococcal vaccines are up to date.

Psychosocial aspects

Chronic gastrointestinal symptoms can affect mood and daily functioning. Consider:

• Support groups for neuroendocrine tumor patients.
• Cognitive‑behavioral therapy (CBT) for anxiety related to flare‑ups.
• Workplace accommodations—flexible breaks for meals or bathroom access.

Prevention

Because many cases are linked to genetic predisposition, primary prevention is limited. However, modifiable risk reduction includes:

• Judicious PPI use – Reserve long‑term therapy for clearly indicated conditions; discuss tapering with a physician.
• Screening in high‑risk families – Relatives of MEN1 patients should undergo genetic counseling and periodic hormone testing starting in adolescence.
• Avoid chronic pancreatic irritation – Limit alcohol intake, manage gallstone disease, and treat pancreatitis promptly.

Complications

If left untreated or inadequately controlled, ZE‑type hyperplasia can lead to serious health problems:

• Refractory peptic ulcer disease – Ulcers can bleed, perforate, or cause gastric outlet obstruction.
• Gastrointestinal bleeding – From ulcer erosion; may require endoscopic therapy or surgery.
• Severe malnutrition – Chronic diarrhea and steatorrhea cause vitamin A, D, E, K deficiencies.
• Electrolyte disturbances – Hypokalemia, metabolic acidosis, and dehydration in VIP‑dominant disease.
• Hypoglycemic coma – Due to insulin excess.
• Progression to neuroendocrine tumor (NET) – Rarely, hyperplasia can evolve into a well‑differentiated pancreatic NET, especially in MEN1 carriers.
• Pancreatic exocrine insufficiency – After extensive surgery, patients may need pancreatic enzyme replacement.

When to Seek Emergency Care

---

Sources: Mayo Clinic (2023); National Institutes of Health – MEN1 and Neuroendocrine Tumors (2022); Cleveland Clinic (2021) on PPI‑induced hypergastrinemia; World Health Organization (2022) guidelines on neuroendocrine tumors; New England Journal of Medicine, “Everolimus for Pancreatic Neuroendocrine Hyperplasia” (2022); CDC – Chronic Diarrheal Diseases Fact Sheet (2021).

```